Retatrutide, a new dual activator of the GLP-1 target and glucose-dependent released polypeptide (GIP) binding site , is exhibiting promising outcomes in initial patient studies. Ongoing inquiry https://getsocialsource.com/story6839145/retatrutide-emerging-investigations-and-possible-clinical-roles